Review of Medicinal Cannabis Licensing launched

13th April 2021

​An in-depth review examining the regulations for the licence application, production, and export of medicinal cannabis in Jersey has been launched by the Economic and International Affairs Scrutiny Panel.

As well as comparing the regulations for licence application with other jurisdictions, the Panel will consider its impact on Jersey's international reputation and assess how economically beneficial this new sector will be for the Island. The review will also assess how robust the application process is to ensure thorough due diligence is undertaken on applicants. To inform its review, the Panel will engage with relevant Ministers and industry representatives. Following this, recommendations will be presented to the Minister for Economic Development, Tourism, Sport, and Culture as well as the States Assembly in a mid-June report.

Deputy David Johnson, Chair of the Economic and International Affairs Panel, said "Given that the topic of medicinal cannabis licensing is one of key public interest, we want to reinforce that the review will focus on licensing for medicinal cannabis only. When scrutinising these regulations, we will seek to identify what economic benefit an industry based on the growth, import and export of medicinal cannabis will have on the Island and any additional costs that may affect the taxpayer. Examining the potential impact of the sector, either positive or negative, on the Island's international image, will also inform our review and subsequent recommendations to the Government and the States Assembly."

 Last year, in 2020, the first licences were issued to companies to grow medicinal cannabis in Jersey. Applications for licences, granted under the Misuse of Drugs (Jersey) Law 1978, are only considered where the cannabis will be used to produce a medicinal product manufactured to UK/EU Good Manufacturing Practice (GMP) standards.

Back to news